MX2009011208A - Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5. - Google Patents

Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.

Info

Publication number
MX2009011208A
MX2009011208A MX2009011208A MX2009011208A MX2009011208A MX 2009011208 A MX2009011208 A MX 2009011208A MX 2009011208 A MX2009011208 A MX 2009011208A MX 2009011208 A MX2009011208 A MX 2009011208A MX 2009011208 A MX2009011208 A MX 2009011208A
Authority
MX
Mexico
Prior art keywords
modulators
acid derivatives
nicotinic acid
glutamate receptor
metabotropic glutamate
Prior art date
Application number
MX2009011208A
Other languages
English (en)
Inventor
Ralf Glatthar
David Carcache
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38654771&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009011208A publication Critical patent/MX2009011208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a novedosos derivados de bencimidazol, a su preparación, a su uso como productos farmacéuticos, y a composiciones farmacéuticas que los contienen, en donde los compuestos tienen la fórmula (I): en donde los sustituyentes son como se definen en la reivindicación 1, y sales, solvatos, hidratos y N-óxidos de los mismos.
MX2009011208A 2007-04-19 2008-04-17 Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5. MX2009011208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106537 2007-04-19
PCT/EP2008/054682 WO2008128968A1 (en) 2007-04-19 2008-04-17 Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5

Publications (1)

Publication Number Publication Date
MX2009011208A true MX2009011208A (es) 2009-10-30

Family

ID=38654771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011208A MX2009011208A (es) 2007-04-19 2008-04-17 Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.

Country Status (15)

Country Link
US (1) US20090105266A1 (es)
EP (1) EP2146969A1 (es)
JP (1) JP2010524892A (es)
KR (1) KR20090130141A (es)
CN (1) CN101679299A (es)
AR (1) AR068072A1 (es)
AU (1) AU2008240790A1 (es)
BR (1) BRPI0810653A2 (es)
CA (1) CA2682676A1 (es)
CL (1) CL2008001114A1 (es)
EA (1) EA200901379A1 (es)
MX (1) MX2009011208A (es)
PE (1) PE20090074A1 (es)
TW (1) TW200904425A (es)
WO (1) WO2008128968A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
WO2010135493A2 (en) * 2009-05-20 2010-11-25 Emory University Alzheimer's disease imaging agents
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
JPWO2013081094A1 (ja) * 2011-11-30 2015-04-27 東レ株式会社 イミダゾ［１，２−ａ］ピリジン誘導体及びその医薬用途
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
RU2016103149A (ru) 2013-07-02 2017-08-07 Зингента Партисипейшнс Аг Пестицидно-активные би-или трициклические гетероциклы с серосодержащими заместителями
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
PE20160865A1 (es) 2013-12-19 2016-09-03 Novartis Ag Derivados de [1,2,4] triazolo [1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis
EP3180341B1 (en) 2014-08-12 2022-04-27 Syngenta Participations AG Pesticidally active heterocyclic derivatives with sulphur containing substituents
US10308650B2 (en) 2014-12-11 2019-06-04 Syngenta Participations Ag Pesticidally active tetracyclic derivatives with sulfur containing substituents
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
US10104893B2 (en) 2015-04-24 2018-10-23 Syngenta Participations Ag Pesticidally active polycyclic derivatives with sulfur substituted five membered ring heterocyles
ES2762947T3 (es) 2015-04-24 2020-05-26 Syngenta Participations Ag Derivados policíclicos con actividad plaguicida con anillos heterocíclicos de cinco miembros sustituidos con azufre
BR112018000052A2 (pt) 2015-07-01 2018-09-04 Syngenta Participations Ag derivados policíclicos ativos em termos pesticidas com substituintes contendo enxofre
BR112017028600A2 (pt) 2015-07-01 2018-08-28 Syngenta Participations Ag derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CN108290885A (zh) 2015-11-23 2018-07-17 先正达参股股份有限公司 具有含硫和含环丙基的取代基的杀有害生物活性杂环衍生物
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
IL299415A (en) 2016-06-16 2023-02-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
US10889583B2 (en) 2016-10-27 2021-01-12 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur and hydroxylamine substituents
WO2018091389A1 (en) 2016-11-17 2018-05-24 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
EP3554242A1 (en) 2016-12-15 2019-10-23 Syngenta Participations AG Pesticidally active heterocyclic derivatives with sulfur containing substituents
AU2017387033B2 (en) 2016-12-29 2024-02-01 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562306A4 (en) * 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. METALLOENZYME INHIBITOR COMPOUNDS
JP7191298B2 (ja) 2017-04-26 2022-12-19 バジリア・ファルマスーチカ・インターナショナル・アーゲー，アルシュヴィル フラザノベンズイミダゾール類及びその結晶形の調製方法
WO2018215304A1 (en) 2017-05-22 2018-11-29 Syngenta Participations Ag Tetracyclic pyridazine sulphur containing compounds and their use as pesticides
EP3649118A1 (en) 2017-07-05 2020-05-13 Syngenta Participations AG Pesticidally active heterocyclic derivatives with sulfur containing substituents
MY197923A (en) * 2018-05-22 2023-07-25 Nihon Nohyaku Co Ltd Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same
AR115495A1 (es) 2018-06-06 2021-01-27 Syngenta Crop Protection Ag Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
CN113766915A (zh) * 2019-03-25 2021-12-07 纽约市哥伦比亚大学理事会 用于治疗糖尿病和与胰腺功能受损相关的其他疾患的选择性foxo抑制剂
BR112021020226A2 (pt) * 2019-04-10 2021-12-07 Cellestia Biotech Ag Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
CA3222199A1 (en) * 2021-06-02 2022-12-08 Nihon Nohyaku Co., Ltd. Benzimidazole compound or salt thereof, canine filariasis control agent containing same, and method of use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001227A (es) * 2000-08-08 2004-09-10 Johnson & Johnson Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
WO2005079802A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators

Also Published As

Publication number Publication date
JP2010524892A (ja) 2010-07-22
CN101679299A (zh) 2010-03-24
PE20090074A1 (es) 2009-03-02
US20090105266A1 (en) 2009-04-23
CL2008001114A1 (es) 2008-12-19
BRPI0810653A2 (pt) 2014-11-04
KR20090130141A (ko) 2009-12-17
CA2682676A1 (en) 2008-10-30
EA200901379A1 (ru) 2010-04-30
EP2146969A1 (en) 2010-01-27
TW200904425A (en) 2009-02-01
AR068072A1 (es) 2009-11-04
WO2008128968A1 (en) 2008-10-30
AU2008240790A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
MX2009011208A (es) Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
TW200732323A (en) Organic compounds
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
IN2014CN04127A (es)
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
TW200604183A (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
MX354102B (es) Derivados de bencimidazol-prolina.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2009011816A (es) Derivados de piridina.
MY148634A (en) Pyridazinone derivatives
MX2021004000A (es) Derivados de piperidina.
IL189987A0 (en) Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
RS51661B (en) NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
WO2009050197A3 (en) Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal